Skip to content
I Want Grants
ForecastedFederal · Grants.gov

Discovery Gateway to Reproductive Health Innovation

National Institutes of Health

Description

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks to establish a single Discovery Gateway to Reproductive Health Innovation, a comprehensive knowledgebase designed to advance research on male and female indications such as preeclampsia, endometriosis, preterm birth, infertility, and uterine fibroids. This initiative will expand shared resources and essential infrastructure for the biomedical research community. The Gateway will facilitate integration of existing clinical, pharmacogenomic, and multi-omic data in order to address critical knowledge gaps. By providing open-access, this web-based visualization platform will empower scientists to generate new insights that extend far beyond the scope of individual research efforts. Ultimately, the overarching goal is to catalyze the discovery of new treatments and cures. By identifying potential disease mechanisms, effector genes, biomarkers, and drug targets, the Gateway will drive the development of innovative commercial products and accelerate public-private partnerships. The Discovery Gateway supports multiple implementation recommendations made by the Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC; https://www.nichd.nih.gov/about/advisory/PRGLAC ). Grant authorities that allow NICHD to forecast this opportunity are as follows: 42 U.S.C. 281 (Sec. 401); 42 U.S.C. 285g (Sec. 448); 42 USC 284h (Sec. 409D).

Award amount

Varies, see official page

Eligibility

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Who can apply: Nonprofits, Schools & Colleges, Small Businesses, Government & Tribal, For-Profit Businesses

Location

Nationwide (USA)

Categories

Funding source

Federal Government

Important dates

  • Opens: Oct 20, 2026
  • Deadline: Oct 1, 2027

How to apply

This is a forecasted opportunity. Watch Grants.gov for the official notice; applications open once it is posted. You'll need SAM.gov (UEI) and Grants.gov registrations.

Related grants

ForecastedFederal · Grants.gov

Building Communities of Recovery

Substance Abuse and Mental Health Services Adminis

Award
Varies
Deadline
TBA

The purpose of this program is to support organizations in mobilizing and connecting community resources to increase access to long-term recovery support for people with substance use disorders and co-occurring substance use and mental disorders.

Community and Economic DevelopmentHealth and MedicalMental Health

Last verified Oct 23, 2026

View details
OpenFederal · SBIR.gov

Rapid Comprehensive Diagnostic Test for Multi-System Autoimmune Disease

U.S. Department of Health and Human Services (SBIR)

Award
Varies
Deadline
Sep 30, 2027

The purpose of this topic is to spur the development of novel, rapid diagnostic assays for multi-system autoimmune disease, which represents an unmet healthcare need. Moreover, in its ideal embodiment this diagnostic test might allow typical primary care...

Small BusinessResearch and EvaluationTechnology

Last verified Oct 23, 2026

View details
OpenFederal · Grants.gov

NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)

National Institutes of Health

Award
Varies
Deadline
Feb 3, 2027

The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.

Health and Medical

Last verified Oct 23, 2026

View details